Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Molecular patterns of isolated tubulitis differ from tubulitis with interstitial inflammation in early indication biopsies of kidney allografts

P. Hruba, K. Madill-Thomsen, M. Mackova, J. Klema, J. Maluskova, L. Voska, A. Parikova, J. Slatinska, PF. Halloran, O. Viklicky

. 2020 ; 10 (1) : 22220. [pub] 20201217

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21019631

Grantová podpora
NV17-28778A MZ0 CEP - Centrální evidence projektů

The Banff 2019 kidney allograft pathology update excluded isolated tubulitis without interstitial inflammation (ISO-T) from the category of borderline (suspicious) for acute T cell-mediated rejection due to its proposed benign clinical outcome. In this study, we explored the molecular assessment of ISO-T. ISO-T or interstitial inflammation with tubulitis (I + T) was diagnosed in indication biopsies within the first 14 postoperative days. The molecular phenotype of ISO-T was compared to I + T either by using RNA sequencing (n = 16) or by Molecular Microscope Diagnostic System (MMDx, n = 51). RNA sequencing showed lower expression of genes related to interferon-y (p = 1.5 *10-16), cytokine signaling (p = 2.1 *10-20) and inflammatory response (p = 1.0*10-13) in the ISO-T group than in I + T group. Transcripts with increased expression in the I + T group overlapped significantly with previously described pathogenesis-based transcript sets associated with cytotoxic and effector T cell transcripts, and with T cell-mediated rejection (TCMR). MMDx classified 25/32 (78%) ISO-T biopsies and 12/19 (63%) I + T biopsies as no-rejection. ISO-T had significantly lower MMDx scores for interstitial inflammation (p = 0.014), tubulitis (p = 0.035) and TCMR (p = 0.016) compared to I + T. Fewer molecular signals of inflammation in isolated tubulitis suggest that this is also a benign phenotype on a molecular level.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21019631
003      
CZ-PrNML
005      
20210830101221.0
007      
ta
008      
210728s2020 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41598-020-79332-9 $2 doi
035    __
$a (PubMed)33335257
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Hruba, Petra $u Transplant Laboratory, Institute for Clinical and Experimental Medicine, 140 21, Prague, Czech Republic
245    10
$a Molecular patterns of isolated tubulitis differ from tubulitis with interstitial inflammation in early indication biopsies of kidney allografts / $c P. Hruba, K. Madill-Thomsen, M. Mackova, J. Klema, J. Maluskova, L. Voska, A. Parikova, J. Slatinska, PF. Halloran, O. Viklicky
520    9_
$a The Banff 2019 kidney allograft pathology update excluded isolated tubulitis without interstitial inflammation (ISO-T) from the category of borderline (suspicious) for acute T cell-mediated rejection due to its proposed benign clinical outcome. In this study, we explored the molecular assessment of ISO-T. ISO-T or interstitial inflammation with tubulitis (I + T) was diagnosed in indication biopsies within the first 14 postoperative days. The molecular phenotype of ISO-T was compared to I + T either by using RNA sequencing (n = 16) or by Molecular Microscope Diagnostic System (MMDx, n = 51). RNA sequencing showed lower expression of genes related to interferon-y (p = 1.5 *10-16), cytokine signaling (p = 2.1 *10-20) and inflammatory response (p = 1.0*10-13) in the ISO-T group than in I + T group. Transcripts with increased expression in the I + T group overlapped significantly with previously described pathogenesis-based transcript sets associated with cytotoxic and effector T cell transcripts, and with T cell-mediated rejection (TCMR). MMDx classified 25/32 (78%) ISO-T biopsies and 12/19 (63%) I + T biopsies as no-rejection. ISO-T had significantly lower MMDx scores for interstitial inflammation (p = 0.014), tubulitis (p = 0.035) and TCMR (p = 0.016) compared to I + T. Fewer molecular signals of inflammation in isolated tubulitis suggest that this is also a benign phenotype on a molecular level.
650    _2
$a alografty $x metabolismus $x patologie $7 D064591
650    12
$a biologické markery $7 D015415
650    _2
$a biopsie $7 D001706
650    _2
$a výpočetní biologie $7 D019295
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a stanovení celkové genové exprese $7 D020869
650    _2
$a rejekce štěpu $x etiologie $x metabolismus $x patologie $7 D006084
650    _2
$a přežívání štěpu $x genetika $x imunologie $7 D006085
650    _2
$a vysoce účinné nukleotidové sekvenování $7 D059014
650    _2
$a lidé $7 D006801
650    12
$a transplantace ledvin $x škodlivé účinky $7 D016030
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a intersticiální nefritida $x diagnóza $x etiologie $7 D009395
650    _2
$a transkriptom $7 D059467
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Madill-Thomsen, Katelynn $u Alberta Transplant Applied Genomics Centre, Edmonton, AB, T6G 2S2, Canada $u University of Alberta, Edmonton, AB, T6G 2S2, Canada
700    1_
$a Mackova, Martina $u Alberta Transplant Applied Genomics Centre, Edmonton, AB, T6G 2S2, Canada
700    1_
$a Klema, Jiri $u Department of Computer Science, Faculty of Electrical Engineering, Czech Technical University, 121 35, Prague, Czech Republic
700    1_
$a Maluskova, Jana $u Department of Pathology, Institute for Clinical and Experimental Medicine, 140 21, Prague, Czech Republic
700    1_
$a Voska, Ludek $u Department of Pathology, Institute for Clinical and Experimental Medicine, 140 21, Prague, Czech Republic
700    1_
$a Parikova, Alena $u Department of Nephrology, Transplant Centre, Institute for Clinical and Experimental Medicine, Videnska 1958/9, 14021, Prague, Czech Republic
700    1_
$a Slatinska, Janka $u Department of Nephrology, Transplant Centre, Institute for Clinical and Experimental Medicine, Videnska 1958/9, 14021, Prague, Czech Republic
700    1_
$a Halloran, Philip F $u Alberta Transplant Applied Genomics Centre, Edmonton, AB, T6G 2S2, Canada
700    1_
$a Viklicky, Ondrej $u Transplant Laboratory, Institute for Clinical and Experimental Medicine, 140 21, Prague, Czech Republic. ondrej.viklicky@ikem.cz $u Department of Nephrology, Transplant Centre, Institute for Clinical and Experimental Medicine, Videnska 1958/9, 14021, Prague, Czech Republic. ondrej.viklicky@ikem.cz
773    0_
$w MED00182195 $t Scientific reports $x 2045-2322 $g Roč. 10, č. 1 (2020), s. 22220
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33335257 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830101221 $b ABA008
999    __
$a ok $b bmc $g 1690447 $s 1140077
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 10 $c 1 $d 22220 $e 20201217 $i 2045-2322 $m Scientific reports $n Sci Rep $x MED00182195
GRA    __
$a NV17-28778A $p MZ0
LZP    __
$a Pubmed-20210728

Najít záznam

Citační ukazatele

Možnosti archivace